Get the Stockscreener App
36.21
2.71%
-1.01
After Hours:
36.21
Xenon Pharmaceuticals Inc stock is traded at $36.21, with a volume of 562.31K.
It is down -2.71% in the last 24 hours and up +0.61% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$37.22
Open:
$37.11
24h Volume:
562.31K
Relative Volume:
0.54
Market Cap:
$2.79B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-13.22
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
-7.65%
1M Performance:
+0.61%
6M Performance:
+2.06%
1Y Performance:
-8.03%
1-Day Range:
$36.19
$37.22
1-Week Range:
$36.19
$38.91
52-Week Range:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
36.21 | 2.86B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Alliancebernstein L.P. Cuts Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Parkman Healthcare Partners LLC Sells 18,428 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Design Therapeutics Appoints Justin Gover to Board of Directors - The Globe and Mail
Alyeska Investment Group L.P. Has $12.32 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report? - Yahoo Finance
RSI and MACD Indicate Shift in Xenon Pharmaceuticals Inc. Sentiment - beatles.ru
Trapped Investors in Xenon Pharmaceuticals Inc. Await Breakout Signal2025 Valuation Update & Community Verified Swing Trade Signals - beatles.ru
Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals' (XENE) Outperform Rating Reaffirmed at Royal Bank Of Canada - MarketBeat
Price momentum metrics for Xenon Pharmaceuticals Inc. explainedDividend Hike & AI Driven Stock Price Forecasts - Newser
How to build a custom watchlist for Xenon Pharmaceuticals Inc.July 2025 Update & Free Long-Term Investment Growth Plans - Newser
Vestal Point Capital LP Purchases 490,000 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Braidwell LP Decreases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Can Xenon Pharmaceuticals Inc. sustain its profitabilityJuly 2025 Movers & Fast Gaining Stock Strategy Reports - خودرو بانک
What is Xenon Pharmaceuticals Inc.’s market positionMarket Risk Report & Stepwise Entry and Exit Trade Signals - خودرو بانک
Can swing trading help recover from Xenon Pharmaceuticals Inc. lossesRisk Management & Daily Risk Controlled Trade Plans - Newser
Chart based analysis of Xenon Pharmaceuticals Inc. trends2025 Breakouts & Breakdowns & Risk Controlled Stock Alerts - Newser
Understanding Xenon Pharmaceuticals Inc.’s price movementWeekly Trend Summary & Entry Point Confirmation Signals - Newser
Building trade automation scripts for Xenon Pharmaceuticals Inc.Weekly Trade Summary & Technical Pattern Based Signals - Newser
Is Xenon Pharmaceuticals Inc. a speculative investmentTrade Analysis Summary & Low Drawdown Investment Strategies - خودرو بانک
Can Xenon Pharmaceuticals Inc. deliver consistent dividendsWeekly Investment Summary & Growth Focused Entry Point Reports - خودرو بانک
Ranking Xenon Pharmaceuticals Inc. among high performing stocks via toolsJuly 2025 Technicals & Verified Momentum Stock Watchlist - Newser
How to use Fibonacci retracement on Xenon Pharmaceuticals Inc.2025 Pullback Review & Daily Stock Trend Reports - Newser
Can machine learning forecast Xenon Pharmaceuticals Inc. recoveryWeekly Earnings Recap & Low Volatility Stock Suggestions - Newser
How does Xenon Pharmaceuticals Inc. compare to its peersEarnings Trend Report & Low Risk High Win Rate Picks - خودرو بانک
Momentum divergence signals in Xenon Pharmaceuticals Inc. chartWeekly Trade Review & Long-Term Safe Investment Plans - Newser
Analyzing Xenon Pharmaceuticals Inc. with risk reward ratio chartsJuly 2025 Closing Moves & High Return Stock Watch Alerts - Newser
Price action breakdown for Xenon Pharmaceuticals Inc.July 2025 Closing Moves & Technical Pattern Based Buy Signals - Newser
Xenon (XENE) Receives a Buy from RBC Capital - The Globe and Mail
Applying Elliott Wave Theory to Xenon Pharmaceuticals Inc.2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
Will Xenon Pharmaceuticals Inc. benefit from rate cutsGap Up & Low Drawdown Investment Ideas - خودرو بانک
Published on: 2025-09-03 01:33:36 - Newser
Using AI based signals to follow Xenon Pharmaceuticals Inc.CPI Data & AI Powered Buy and Sell Recommendations - Newser
Predicting Xenon Pharmaceuticals Inc. trend using moving averagesBuy Signal & Safe Capital Growth Plans - Newser
Volume Recap: Can Xenon Pharmaceuticals Inc. navigate macro headwindsQuarterly Investment Review & Real-Time Chart Breakout Alerts - خودرو بانک
Developing predictive dashboards with Xenon Pharmaceuticals Inc. dataPortfolio Performance Summary & Weekly Market Pulse Alerts - Newser
What is Xenon Pharmaceuticals Inc.’s book value per sharePortfolio Update Summary & Real-Time Volume Triggers - خودرو بانک
Xenon Pharmaceuticals shares fall 1.50% premarket after equity inducement grants to new employees. - AInvest
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN
Is Xenon Pharmaceuticals Inc. reversing from oversold territory2025 Trading Recap & Intraday High Probability Alerts - Newser
Using RSI to spot recovery in Xenon Pharmaceuticals Inc.Weekly Trade Review & Smart Investment Allocation Tips - Newser
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):